Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) – HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Xeris Biopharma in a report released on Friday, May 8th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.07 per share for the year, up from their previous forecast of $0.06. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.12 per share. HC Wainwright also issued estimates for Xeris Biopharma’s FY2028 earnings at $0.37 EPS and FY2029 earnings at $0.67 EPS.
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%.
Read Our Latest Report on XERS
Xeris Biopharma Stock Down 6.0%
XERS opened at $6.14 on Tuesday. The company has a market cap of $1.06 billion, a PE ratio of 102.33 and a beta of 0.85. Xeris Biopharma has a twelve month low of $4.30 and a twelve month high of $10.08. The company has a 50-day moving average price of $5.90 and a 200 day moving average price of $6.92. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00.
Insider Buying and Selling
In other Xeris Biopharma news, Director James Aloysius Brady sold 10,834 shares of the firm’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $5.54, for a total value of $60,020.36. Following the completion of the sale, the director owned 89,166 shares of the company’s stock, valued at approximately $493,979.64. This trade represents a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $6.25, for a total value of $104,168.75. Following the completion of the transaction, the insider directly owned 1,226,507 shares of the company’s stock, valued at $7,665,668.75. The trade was a 1.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 60,835 shares of company stock worth $367,860. Corporate insiders own 4.56% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of XERS. AlphaCentric Advisors LLC lifted its stake in Xeris Biopharma by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after buying an additional 2,494 shares in the last quarter. KBC Group NV purchased a new position in Xeris Biopharma during the first quarter worth $27,000. Swiss National Bank raised its holdings in shares of Xeris Biopharma by 3.1% in the first quarter. Swiss National Bank now owns 328,300 shares of the company’s stock worth $1,904,000 after acquiring an additional 9,900 shares during the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Xeris Biopharma in the first quarter valued at $1,204,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Xeris Biopharma by 38.5% during the first quarter. Principal Financial Group Inc. now owns 208,507 shares of the company’s stock valued at $1,209,000 after acquiring an additional 57,948 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.
Xeris Biopharma Company Profile
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Read More
- Five stocks we like better than Xeris Biopharma
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
